Arvinas and Pfizer to out-license vepdegestrant commercialization rights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
September 17, 2025 4:30 PM EDTArvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant
Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024
Board authorizes stock repurchase program of up to $100 million
Reaffirms cash runway guidance through the second half of 2028
NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today provided an update on its collaboration with Pfizer Inc. (NYSE: PFE) for the... More
